WP
GALT icon

WealthPLAN Partners’s Galectin Therapeutics GALT Stock Holding History

WealthPLAN Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.77K Sell
2,500
-2,500
-50% -$4.45K ﹤0.01% 814
2016
Q2 		$3.68K Buy
+5,000
New +$7.33K ﹤0.01% 2087
2015
Q4 		$4.11K Buy
+7,500
New +$17.2K ﹤0.01% 1373
2015
Q2 		$7K Hold
2,500
– – ﹤0.01% 326
2015
Q1 		$8K Buy
+2,500
New +$8.93K ﹤0.01% 393

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

WealthPLAN Partners's GALT Position: Q3 2016 in Review

WealthPLAN Partners reduced its Galectin Therapeutics (GALT) stake by 50% in Q3 2016, selling an estimated $4.45K and leaving 2,500 shares worth $2.77K. The position accounts for ﹤0.01% of the portfolio, ranked #814.

WealthPLAN Partners first reported a position in GALT in Q1 2015 and has held it in 5 quarters since. The position peaked at $8K in Q1 2015. 46 funds tracked by Wall St. Rank hold GALT as of Q3 2016.

  • WealthPLAN Partners held 2,500 shares of Galectin Therapeutics worth $2.77K as of Q3 2016.
  • WealthPLAN Partners sold 2,500 Galectin Therapeutics shares in Q3 2016, an estimated $4.45K.
  • Galectin Therapeutics made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #814 holding.
  • WealthPLAN Partners first reported a position in Galectin Therapeutics in Q1 2015 and has held it in 5 quarters since.
  • WealthPLAN Partners's Galectin Therapeutics position peaked at $8K in Q1 2015.
  • 46 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.